Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Research reported that the DMDRMR/miR-378a-5p/ DAB2IP axis enhances angiogenesis and sunitinib resistance, suggesting that it could be used for patients with ccRCC.
Research headed by Professor Xiujun Cai used the CRISPR/cas9 system to screen the entire genome of hepatocellular carcinoma cells (HepG2) under sorafenib treatment.
This study is led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine). Professor Xiujun Cai's research team screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system under sorafenib treatment, and screened the dominant gene in sorafenib resistance.